Alphatec Stock Crashes 39%: Worst Day in a Decade

Alphatec Holdings (NASDAQ: ATEC) stock crashed about 39% on Friday, October 30, 2026, falling to around $6.90 after the spine-surgery company missed third-quarter estimates and cut its full-year revenue outlook. The drop put the shares on track for their worst single day since August 5, 2015, according to Dow Jones Market Data cited by Barron's, and sent the stock to a new 52-week low. The trigger was not collapsing demand for spine surgery — it was a slump in the company's high-margin bone-graft business, known as biologics.

What happened to Alphatec stock today?

Alphatec reported third-quarter results after the close on Thursday, October 29. Revenue grew about 13% year over year to $221 million, but that missed Wall Street's expectations of roughly $225 million. Adjusted earnings of $0.09 per share also came in just below the $0.10 consensus estimate. Investors focused less on the small miss itself and more on what came with it: management cut full-year 2026 revenue guidance to approximately $862 million, down from the $882 million the company had reaffirmed only three months earlier after its second-quarter report. Shares, which had closed Thursday at $11.37, gapped down at Friday's open and traded as low as about $6.81 — below the previous 52-week low — on volume several times the daily average.

The biologics problem behind the selloff

The core issue is what Barron's described as a cross-selling problem. Alphatec sells surgical hardware — the implants and instruments used in spinal fusion — and it also sells biologics, the bone-graft substitutes placed alongside those implants. Biologics are high-margin products, and in a typical year they contribute $15 million to $25 million of the company's growth. This quarter they went backwards: biologics sales fell by roughly $1 million from a year ago, even though total surgical case volumes grew about 20%. Because fewer procedures included Alphatec's biologics, revenue per case fell about 5%. Management attributed the weakness to a lack of sales discipline and increased competition from smaller providers, and now expects biologics revenue to be flat this year rather than a growth contributor. CEO Pat Miles acknowledged the shortfall directly on the earnings call: "Third-quarter revenue fell short of our expectations, primarily due to lower biologics attachment," adding that improving biologics performance is now a clear priority.

Why the guidance cut hit so hard

Guidance cuts damage credibility most when they reverse a recent reaffirmation, and that is exactly what happened here. Alphatec had stood behind its outlook after the second quarter, so the move down to about $862 million — including roughly $789 million of surgical revenue and about $73 million from its EOS imaging business — landed as a surprise. The company also pointed to softer thoracolumbar procedure volumes, which it believes reflect broader market trends, and a temporary international supply constraint expected to cost about $3 million of sales this year. Needham analyst David Saxon warned on Friday that zero growth in biologics over the next year puts Alphatec's 2027 goals at risk, even though the company has beaten its multiyear plan so far. With the stock already down about 46% in 2026 heading into Friday's session, there was little patience left for a reset.

What is still working at Alphatec

The selloff was not driven by the whole business deteriorating. Surgical revenue rose 14% to $202 million, surgical hardware revenue grew 17% and contributed $26 million of growth, and new surgeon adoption jumped 25% — the strongest single quarter of new surgeon additions in the company's history, according to the earnings call. Adjusted EBITDA rose 46% to $38 million in the quarter, and Alphatec kept its full-year adjusted EBITDA guidance at about $137 million, a roughly 16% margin, despite the lower revenue outlook. The company also generated positive free cash flow for a fifth consecutive quarter and repaid the remaining balance of its 2026 notes with cash on hand, ending September with about $80 million in cash. In other words, more surgeons are using more Alphatec hardware than ever — the company is simply earning less on each procedure than investors had modeled.

What happens next

The next test is whether the biologics fix management described — changes made during the third quarter that it says were already showing improvement as the quarter ended — translates into a fourth-quarter recovery. Guidance implies flat biologics revenue from the third quarter to the fourth, so any upside there would be a positive surprise. Investors will also watch upcoming reports from spine and medtech peers such as Globus Medical and Medtronic for evidence on whether softer procedure volumes are an industry trend or an Alphatec-specific problem. For now, Friday's move resets expectations sharply: the market is pricing Alphatec on what it earned per case today, not on the growth story it told three months ago. This article reports market news only and is not financial advice.

FAQ

Why did Alphatec stock fall 39% today?

Alphatec missed third-quarter revenue and earnings estimates and cut its full-year 2026 revenue outlook to about $862 million from $882 million, after weakness in its high-margin biologics (bone-graft) business reduced revenue per procedure.

What are Alphatec's biologics, and why do they matter?

Biologics are bone-graft substitutes used in spinal fusion surgery alongside Alphatec's implants. They are high-margin products that normally add $15 million to $25 million of annual growth; this quarter their sales fell about $1 million year over year and are now expected to be flat for the year.

What were Alphatec's Q3 2026 results?

Revenue rose about 13% to $221 million versus roughly $225 million expected, and adjusted earnings were $0.09 per share versus $0.10 expected. Surgical revenue grew 14% to $202 million, case volumes rose about 20%, and adjusted EBITDA increased 46% to $38 million.

Is this Alphatec's worst stock drop ever?

Friday's decline put the shares on track for their worst single-day percentage drop since August 5, 2015, according to Dow Jones Market Data cited by Barron's, and the stock set a new 52-week low near $6.81.